Venture Philanthropy Strategies to Support Translational Research Workshop Summary (2009) / Chapter Skim
Currently Skimming:
Introduction
Introduction
Pages 1-8
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 1... ...
Historically, this giving fell under a few key areas: buying and distributing medicine; providing food, care, and shelter to those in need; offering education; and delivering prophylactic equipment to target areas, such as mosquito nets in malaria-stricken regions. In addition, many voluntary health organizations have supported basic research, helping to seed the development of innovative treatment ideas that commercial pharmaceutical and biotech companies can advance into the clinic and develop into novel therapies.
|
From page 2... ...
Workshop chair Timothy Coetzee, executive director of Fast Forward of the National Multiple Sclerosis Society, noted that embracing venture philanthropy does not mean turning away from original and basic science research. In explaining why the dynamics are shifting, he reiterated that while supporting scientific discovery is still important, it is also important to develop new funding models that bring products into the clinic.
|
From page 3... ...
The Need and Risks The reality is that drug development -- even for large, relatively wellfunded diseases -- is a very slow process. Joyce Nelson, president and chief executive officer of the National Multiple Sclerosis Society, shared some sobering statistics during the workshop's opening remarks.
|
From page 4... ...
Because the term is so broad, it can be difficult to bring organizational focus to the shared challenges and opportunities that a full-spectrum approach to venture philanthropy can bring. Dennis Choi, vice president of Academic Health Affairs at Emory University, discussed a commonly agreed upon schematic of translational research that begins at the identification and validation of targets for research and ends with clinical research trials (Figure I-1)
|
From page 5... ...
Because the central nervous system is so complex and provides difficulties for drug development, the current linear model where different players work independently from each other simply does not work in his opinion. Choi illustrated a different model where in a precompetitive space, each entity works in partnership to advance science in an environment of collaboration (Figure I-3)
|
From page 6... ...
Recognizing that there was much that voluntary health organizations could learn from each other's efforts, an independent planning committee of the Forum organized a workshop to discuss this new model for financing medical research. The workshop convened a group of key stakeholders and experts representing a variety of voluntary health organizations involved in venture philanthropy–supported translational research and tasked them with identifying and sharing the best practices used, and lessons learned, in order to improve efficiency and effectiveness in translational research.
|
From page 7... ...
The workshop was co-chaired by Timothy Coetzee, executive director of Fast Forward of the National Multiple Sclerosis Society, and William Thies, vice president for medical and scientific relations at the Alzheimer's Association. In this workshop summary, key pieces of advice and experiences are attributed to one individual, or when multiple parties were involved with fashioning or honing a single idea or insight, the idea is attributed to the key parties involved.
|
From page 8... ...
is just as important as what the patients provide the organization -- be open and prepared to really listen to the patient community. A complete list of key points can be found at the end of each chapter.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.